Business Wire

CA-GILEAD-SCIENCES

28.3.2022 17:02:07 CEST | Business Wire | Press release

Share
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere

Gilead Sciences, Inc., (Nasdaq: GILD) today announced $24 million in grants to help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic. The Zeroing In: Ending the HIV Epidemic program, will support 116 organizations in 41 countries. The funding recipients will focus on advancing at least one of three focus areas: Comprehensive HIV Innovation, Digital Health Innovation and Community Outreach and Education.

“While the HIV community has made tremendous progress toward ending the HIV epidemic, the COVID-19 pandemic created barriers and amplified health inequities in the most marginalized communities,” said Alex Kalomparis, Senior Vice President, Public Affairs, Gilead Sciences. “We are working with organizations that will reach under-resourced communities and support them to find innovative, effective solutions. Zeroing In programs aim to increase access to HIV care and services and build on Gilead’s efforts to help end the epidemic for everyone, everywhere.”

“Through Gilead Sciences’ Zeroing In program, a collective of 10 migrant-led frontline organizations across Europe have the opportunity to work collectively for the first time to address HIV knowledge, testing and treatment barriers amongst migrant communities,” said Denis Onyango, Programmes Director, Africa Advocacy Foundation.

“Through this funding, we will be able to increase community awareness of HIV and PrEP to marginalized communities across Mississippi, through trained community health workers. We plan to address HIV stigma, and structural and institutional barriers associated with HIV care in Mississippi. It is only through support from organizations like Gilead that we will truly be able to end the HIV epidemic,” said Dr. Christopher Roby, Chief Operations Officer, Community Health Center Association of Mississippi.

“This funding will empower very isolated families to manage their HIV at home and to quickly access medical care when additional support is needed, without creating undue financial burdens on families that are experiencing significant hardship. It will also help us combat the devastating stigma that exists around HIV throughout Nepal. This will make it easier to access care, maintain community ties, and keep safe and healthy,” said Crystal Anderson, Grants and Donor Communications Manager, Nepal Youth Foundation.

To build on progress in local communities, Zeroing In organizations will prioritize populations most affected by the HIV epidemic. This includes projects from local organizations collaborating to end the HIV epidemic in their respective cities, states, countries or regions. Zeroing In organizations will focus on one or more of three areas:

  • Comprehensive HIV Innovation Programs: This includes at-home testing efforts that help close the gaps in HIV testing and prevention, supportive service programs and comprehensive HIV prevention programs inclusive of biomedical prevention options.
  • Digital Health Innovations : Strategies will address the health literacy divide in accessing digital health services, support digital access in rural areas for better outcomes for people living with HIV, or support digital health education for those with language barriers, aging populations, indigenous, migrant and stigmatized populations.
  • Community Outreach and Education: Community-driven programs will provide resources for HIV community outreach workers, address the lack of culturally appropriate service options, break down barriers between communities and service providers, and reduce stigma and improve education around HIV.

About Zeroing In

Zeroing In builds on previous Gilead funding and grant programs, while supporting organizations to increase the overall health and wellness of communities most impacted by HIV and COVID-19. Gilead provides support to organizations whose programs align with international and country-specific Ending the HIV Epidemic goals. This includes local community programming and coalition-led proposals from organizations collaborating to end the HIV epidemic in their respective city, state, country or region. Zeroing In programming focuses on comprehensive HIV innovation, digital health innovation, and/or community outreach and education.

For more information on Gilead’s Zeroing In: Ending the HIV Epidemic grant program, please visit https://www.gilead.com/purpose/giving/zeroing-in-ending-hiv-epidemic . A complete list of funded organizations can be found at https://www.gilead.com/-/media/files/pdfs/other/Zeroing-In-Grantee-List-for-Website.pdf .

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Today, millions of people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. All other trademarks are the property of their respective owners.

For more information about Gilead, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global and China Gas Announce Increased Long-Term LNG Agreement18.11.2026 01:00:00 CET | Press release

Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of an increased Sales and Purchase Agreement (SPA) for the total purchase of 1.0 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement upsizes the previous SPA announced by the two parties in September 2026 for the purchase of 0.5 MTPA by another newly-agreed 0.5 MTPA. Venture Global’s total current long-term offtake with China Gas is now 3.0 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to continue growing our LNG partnership with China Gas, a leading natural gas operator in China, and help meet the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects,” said Venture Global CEO Mike Sabel. "We are pleased to further expa

UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press release

Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products rea

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release

Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye